In April 2016 Manchester eScholar was replaced by the University of Manchester’s new Research Information Management System, Pure. In the autumn the University’s research outputs will be available to search and browse via a new Research Portal. Until then the University’s full publication record can be accessed via a temporary portal and the old eScholar content is available to search and browse via this archive.

Genetic variation in efflux transporters influences outcome to methotrexate therapy in patients with psoriasis.

Warren, Richard B; Smith, Rhodri L L; Campalani, Emanuela; Eyre, Steve; Smith, Catherine H; Barker, Jonathan N W N; Worthington, Jane; Griffiths, Christopher E M

The Journal of investigative dermatology. 2008;128(8):1925.

Access to files

Full-text and supplementary files are not available from Manchester eScholar. Full-text is available externally using the following links:

Full-text held externally

Abstract

Methotrexate, an inexpensive first-line systemic therapy for moderate-to-severe psoriasis, is limited in its use by unpredictable efficacy and toxicity. This study was designed to test the hypothesis that single-nucleotide polymorphisms (SNPs) in methotrexate transmembrane transporters and adenosine receptors are associated with efficacy and/or toxicity of the drug. DNA was collected from 374 patients with chronic plaque psoriasis who had been treated with methotrexate. Phenotypic data on efficacy and toxicity were available. Haplotype tagging SNPs (r(2)>0.8) across the relevant genes, with a minor allele frequency of >5%, were selected from the HAPMAP phase II data. SNPs within the efflux transporter genes ABCC1 (ATP-binding cassette, subfamily C, member 1) and ABCG2 (ATP-binding cassette, subfamily G, member 2) are associated with good response to methotrexate therapy in patients with psoriasis; the former gene was also associated with the onset of toxicity. With one SNP in ABCC1, rs246240, the carriage of two copies of allele 1 gives an odds ratio of 2.2 (95% confidence interval: 1.3-3.6; P=0.001) for developing toxicity to methotrexate. These data indicate that knowledge of SNPs in genes relevant to methotrexate efflux may be important in selecting patients suitable for this therapy.

Bibliographic metadata

Content type:
Published date:
Language:
eng
ISSN:
Place of publication:
United States
Volume:
128
Issue:
8
Start page:
1925
Digital Object Identifier:
10.1038/jid.2008.16
Pubmed Identifier:
18256692
Pii Identifier:
jid200816
Access state:
Active

Institutional metadata

University researcher(s):

Record metadata

Manchester eScholar ID:
uk-ac-man-scw:79538
Created by:
Warren, Richard
Created:
24th April, 2010, 20:06:10
Last modified by:
Warren, Richard
Last modified:
12th March, 2014, 09:15:37

Can we help?

The library chat service will be available from 11am-3pm Monday to Friday (excluding Bank Holidays). You can also email your enquiry to us.